Scot A Marsters

20020146389, Oct 10, 2002

Feb 22, 2002

10/080455

Avi Ashkenazi - San Mateo CA, US
Kevin Baker - San Mateo CA, US
Paul Godowski - Burlingame CA, US
Austin Gurney - Belmont CA, US
Melanie Mark - Burlingame CA, US
Scot Marsters - San Carlos CA, US
Robert Pitti - El Cerrito CA, US

Genentech, Inc.

A61K038/19
C07H021/04
C12P021/02
C12N005/06
C07K014/525

424/085100, 530/351000, 536/023500, 435/325000, 435/320100, 435/069500

A tumor necrosis factor homolog, identified as DNA19355, is provided. DNA19355 polypeptide has apoptotic activity in mammalian cancer cells and may be involved in proinflammatory responses. Nucleic acid molecules encoding DNA19355, chimeric molecules and antibodies to DNA19355 are also provided.

20020150993, Oct 17, 2002

Apr 4, 2002

10/116378

Avi Ashkenazi - San Mateo CA, US
Audrey Goddard - San Francisco CA, US
Austin Gurney - Belmont CA, US
Scot Marsters - San Carlos CA, US
Robert Pitti - El Cerrito CA, US
William Wood - Hillsborough CA, US

Genentech, Inc.

A61K038/17
C07H021/04
C12P021/02
C12N005/06
C07K014/715

435/069500, 435/320100, 435/325000, 530/350000, 536/023500, 514/012000

The present invention is directed to novel polypeptides having homology to members of the tumor necrosis factor receptor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

20030100497, May 29, 2003

Aug 16, 2002

10/223085

Kevin Baker - Darnestown MD, US
Napoleone Ferrara - San Francisco CA, US
Hanspeter Gerber - San Francisco CA, US
Mary Gerritsen - San Mateo CA, US
Audrey Goddard - San Francisco CA, US
Paul Godowski - Hillsborough CA, US
Austin Gurney - Belmont CA, US
Kenneth Hillan - San Francisco CA, US
Scot Marsters - San Carlos CA, US
James Pan - Etobicoke, CA
Jean-Philippe Stephan - Millbrae CA, US
Colin Watanabe - Moraga CA, US
P. Williams - Half Moon Bay CA, US
William Wood - Hillsborough CA, US
Weilan Ye - Foster City CA, US

Genentech, Inc.

A61K038/17
C07K014/435
C12P021/02
C12N005/06
C07H021/04
C12N009/00

514/012000, 530/350000, 536/023200, 435/069100, 435/183000, 435/320100, 435/325000

Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

20030105011, Jun 5, 2003

Aug 16, 2002

10/223084

Kevin Baker - Darnestown MD, US
Napoleone Ferrara - San Francisco CA, US
Hanspeter Gerber - San Francisco CA, US
Mary Gerritsen - San Mateo CA, US
Audrey Goddard - San Francisco CA, US
Paul Godowski - Hillsborough CA, US
Austin Gurney - Belmont CA, US
Kenneth Hillan - San Francisco CA, US
Scot Marsters - San Carlos CA, US
James Pan - Etobicoke, CA
Jean-Philippe Stephan - Millbrae CA, US
Colin Watanabe - Moraga CA, US
P. Williams - Half Moon Bay CA, US
William Wood - Hillsborough CA, US
Weilan Ye - Foster City CA, US

Genentech, Inc.

A61K038/17
C07K014/435
C12P021/02
C12N005/06
C07H021/04
C12N009/00

514/012000, 530/350000, 536/023200, 435/069100, 435/183000, 435/325000, 435/320100

Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

20030105012, Jun 5, 2003

Aug 16, 2002

10/223088

Kevin Baker - Darnestown MD, US
Napoleone Ferrara - San Francisco CA, US
Hanspeter Gerber - San Francisco CA, US
Mary Gerritsen - San Mateo CA, US
Audrey Goddard - San Francisco CA, US
Paul Godowski - Hillsborough CA, US
Austin Gurney - Belmont CA, US
Kenneth Hillan - San Francisco CA, US
Scot Marsters - San Carlos CA, US
James Pan - Etobicoke, CA
Jean-Philippe Stephan - Millbrae CA, US
Colin Watanabe - Moraga CA, US
P. Williams - Half Moon Bay CA, US
William Wood - Hillsborough CA, US
Weilan Ye - Foster City CA, US

Genentech, Inc.

C12P021/02
C12N005/06
C07K014/435
A61K038/17
C07H021/04
C12N009/00

514/012000, 530/350000, 536/023200, 435/069100, 435/325000, 435/320100, 435/183000

Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

20030105013, Jun 5, 2003

Aug 16, 2002

10/223090

Kevin Baker - Darnestown MD, US
Napoleone Ferrara - San Francisco CA, US
Hanspeter Gerber - San Francisco CA, US
Mary Gerritsen - San Mateo CA, US
Audrey Goddard - San Francisco CA, US
Paul Godowski - Hillsborough CA, US
Austin Gurney - Belmont CA, US
Kenneth Hillan - San Francisco CA, US
Scot Marsters - San Carlos CA, US
James Pan - Etobicoke, CA
Jean-Philippe Stephan - Millbrae CA, US
Colin Watanabe - Moraga CA, US
P. Williams - Half Moon Bay CA, US
William Wood - Hillsborough CA, US
Weilan Ye - Foster City CA, US

Genentech, Inc.

A61K038/17
C12P021/02
C12N005/06
C07K014/435
C07H021/04
C12N009/00

514/012000, 530/350000, 536/023200, 435/069100, 435/183000, 435/320100, 435/325000

Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

20030109438, Jun 12, 2003

Aug 16, 2002

10/223087

Kevin Baker - Darnestown MD, US
Napoleone Ferrara - San Francisco CA, US
Hanspeter Gerber - San Francisco CA, US
Mary Gerritsen - San Mateo CA, US
Audrey Goddard - San Francisco CA, US
Paul Godowski - Hillsborough CA, US
Austin Gurney - Belmont CA, US
Kenneth Hillan - San Francisco CA, US
Scot Marsters - San Carlos CA, US
James Pan - Belmont CA, US
Jean-Philippe Stephan - Millbrae CA, US
Colin Watanabe - Moraga CA, US
P. Williams - Half Moon Bay CA, US
William Wood - Hillsborough CA, US
Weilan Ye - Foster City CA, US

Genentech, Inc.

A61K038/17
C07H021/04
C12N009/00
C12P021/02
C12N005/06
C07K014/435

514/012000, 530/350000, 536/023200, 435/069100, 435/183000, 435/320100, 435/325000

Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

20030119112, Jun 26, 2003

Aug 16, 2002

10/223083

Kevin Baker - Darnestown MD, US
Napoleone Ferrara - San Francisco CA, US
Hanspeter Gerber - San Francisco CA, US
Mary Gerritsen - San Mateo CA, US
Audrey Goddard - San Francisco CA, US
Paul Godowski - Hillsborough CA, US
Austin Gurney - Belmont CA, US
Kenneth Hillan - San Francisco CA, US
Scot Marsters - San Carlos CA, US
James Pan - Etobicoke, CA
Jean-Philippe Stephan - Millbrae CA, US
Colin Watanabe - Moraga CA, US
P. Williams - Half Moon Bay CA, US
William Wood - Hillsborough CA, US
Weilan Ye - Foster City CA, US

Genentech, Inc.

C12P021/02
C12N005/06
C07K014/435
C07H021/04
C12N009/00

435/069100, 435/183000, 435/320100, 435/325000, 530/350000, 536/023200

Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.